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LPA is a component of oxidized low density lipoproteins (oxLDL) which has 
been shown to accumulate in human atherosclerotic plaques. Tissue factor {TF) is the 
principal initiator of blood coagulation. Tissue factor upregulation in atherosclerotic 
plaque can lead to undesirable vascular thrombosis. The generation of reactive oxygen 
species (ROS), which act as signaling molecules in the vascular system, is enhanced in 
response to injury and has been associated with a procoagulant state and the progression 
of atherosclerotic disease. Oxidative stress might contribute to the increased expression 
of proatherosclerotic genes at sites of vascular injury, including TF. Little is known about 
the regulation of TF by LPA in smooth muscle cells (SMC) which is a major player in the 
process of atherosclerosis. Data generated by this study demonstrate that LP A markedly 
induces TF expression in rat aorta smooth muscle cells (RASMCs) and human aorta 
smooth muscle cells (HASMCs). The signaling pathways involved are multiple. One 
signaling pathway demonstrates that LP A activates Gai protein which in tum activates 
PKC and MAPK cascades to induce Egr-1 that is involved in turning on TF gene in the 
nucleus. The other pathways include LP A-induced release of ROS and calcium, mediated 
by PLA2 or without PLA2 involvement. Our data suggest that elevated LP A have 
potential atherogenic and thrombogenic actions by inducing TF expression and ROS 
release. Understanding the mechanisms involved could provide new insights into 
atherosclerosis, thrombosis and restenosis after angioplasty. 
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I. BACKGROUND AND INTRODUCTION 
Cardiovascular diseases are the number one cause of death in the United States 
[Groer, 2001]. Atherosclerosis is a progressive cardiovascular disease characterized by 
accumulation of lipids and fibrous elements in the arteries. Atherosclerosis primarily 
affects elastic arteries (e.g., aorta) and large and medium-sized muscular arteries (e.g., 
coronary arteries). This disease is the primary cause of heart disease and stroke. In 
Westernized societies, it is the underlying cause of about 50% of all deaths [Lusis, 2000]. 
THE NORMAL ARTERY: 
The arterial wall normally consists of three well-defined concentric layers: the 
innermost layer is called the intima, the middle layer is called the media, and the 
outermost layer is known as the adventitia. These three layers are demarcated by 
concentric layers of elastin known as the internal elastic lamina (which separates the 
intima from the media), and the external elastic lamina (which separates the media from 
the adventitia). 
The luminal surface of arteries is lined by a single contiguous layer of endothelial 
cells that sits upon a basement membrane of extracellular matrix, and is bordered by the 
internal elastic lamina. The amount of extracellular matrix and elastin in the internal 
elastic lamina is most prominent in medium and large sized arteries. 
The media consists of a single cell type, smooth muscle cells. There can be one or 
many layers of smooth muscle cells depending on the size of the artery [Keaney Jr, 
2000].The vascular smooth muscle has been shown to be a pleiotropic cell capable of 
phenotypic changes associated with the synthesis of many biologically active molecules 
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that mediate cell growth, death, and migration, as well as matrix modulation and 
inflammation. These activities of vascular smooth muscle play important roles in 
physiological vascular functions, such as vascular remodeling, and in pathological 
disorders, such as atherosclerosis, restenosis, transplant vasculopathy, and other vascular 
diseases [Alexander and Dzau, 2000]. The media can vary in size considerably based on 
the function of a given artery. For example, in very small arteries the media may only be 
one cell layer thick, or not present at all, whereas in large arteries like the aorta the media 
may be many cell layers thick and consist of considerable elastin as part of the 
extracellular matrix. 
Beyond the external elastic lamina, the adventitia is the outermost layer of the artery. 
The adventitia typically consists of a loose matrix of elastin, smooth muscle cells, 
fibroblasts, and collagen. This layer contains small vessels that gives rise to vasa 
vasorum. Most of the neural input into blood vessels also traverse the adventitia [Keaney 
Jr, 2000; A vrum et al, 1999] 
ATHEROSCLEROSIS: 
·The early lesions of atherosclerosis (fatty streaks) consist of subendothelial 
accumulations of cholesterol-engorged macrophage, called foam cells. These lesions are 
not clinically significant, but they are the precursors of more advanced lesions 
( atheromatous plaques). An atheromatous plaque consists of a raised focal plaque within 
the intima, having a necrotic core of lipid and a covering fibrous cap. The superficial 
fibrous cap is composed of smooth muscle cells with a few leukocytes and relatively 
dense connective tissue. The lipid necrotic core lies deeper to the fibrous cap and it 
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consists of a disorganized mass of lipid material, cholesterol clefts, cellular debris, lipid­
laden foam cells, fibrin, thrombus in various stages of organization, and other plasma 
proteins. The lipids in the core are primarily cholesterol and cholesterol esters. Foam cells 
predominantly derive from lipid-laden macrophages, but smooth muscle cells can also 
take up lipids to become foam cells. A primary initiating event in atherosclerosis is the 
accumulation of LDL in the subendothelial matrix. Accumulation is greater when levels 
of circulating LDL are raised [Schoen and Cotran, 1999]. Native LDL is not taken up by 
macrophages rapidly enough to generate foam cells, and it has been shown that trapped 
LDL does undergo modification, including oxidation, lipolysis, proteolysis and 
aggregation. These modifications contribute to inflammation and foam cell formation 
[Boren et al, 1998]. If the hypercholesterolemia persists, smooth muscle cell proliferation 
and extracellular matrix deposition in the intima continue and are the major processes that 
convert a fatty streak into a mature fibrofatty atheroma (plaque), accounting for the 
progressive growth of atherosclerotic lesions [Schoen and Cotran, 1999]. Plaques can 
become increasingly complex, with calcification, ulceration at the luminal surface, and 
hemorrhage from small vessels that grow into the lesion from the media of the blood 
vessel wall. The most important clinical complication is acute occlusion due to super 
imposed thrombosis which usually occurs on disrupted lesions (those with rupture, 
ulceration, erosion, or hemorrhage) [Lusis, 2000; Schoen and Cotran 1999]. Acute 
thrombosis can lead to arterial occlusion and consequently provoke myocardial infarction, 
unstable angina, stroke and sudden death [Tremoli et al, 1999]. 
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TISSUE FACTOR: 
Pathological studies have identified tissue factor (TF), present in cells and in the extra 
cellular debris within the atherosclerotic plaque, as a candidate molecule responsible for 
the thrombogenicity associated with the plaque rupture [Fuster et al, 1997]. TF, a small 
(47kd) transmembrane glycoprotein, is the principal initiator of the clotting cascade and is 
considered to be a major regulator of hemostasis and thrombosis [Marmur et al, 1994; 
Edgington et al, 1991]. TF initiates the extrinsic pathway of blood coagulation 
[Schonbeck et al, 2000]. The ultimate events of this cascade are thrombin generation and 
thrombin-catalyzed events which lead to thrombus formation and stabilization [Carson 
and Brozna, 1993]. TF might also affect intimal area by increasing matrix accumulation 
and stimulating smooth muscle cell (SMC) migration and proliferation contributing to 
athermatous plaque development [Hasenstab et al, 2000]. The data so far available from 
samples retrieved by coronary atherectomy suggests that TF plays a critical rule in 
determining atherosclerotic plaque thrombogenicity. Thrombus evident on histology has 
been found only in TF-positive plaques [Marmur et al, 1994] and TF antigen and activity 
were higher in the plaques with complex morphology or coronary thrombosis at 
angiography [Ardissino et al, 1997]. TF concentration and activity were also higher in the 
plaques taken from patients with unstable angina or myocardial infarction, and in patients 












In normal arteries, little or no TF is found in the intima or media, whereas TF is 
abundant in the adventitia [Merlini et al, 1999]. TF is not constitutively expressed by the 
normal artery endothelium or by cellular components of blood. In healthy tissue, this 
distribution allows the endothelium to provide an anticoagulant surface lining the vessel 
lumen, and the adventitia a procoagulant surface around the vessel, ensuring prompt 
initiation- of coagulation in the event of vascular rupture [Mc Vey, 1999]. Vascular 
smooth muscle cells (SMCs) is a major source of arterial TF [Speidel et al, 1995]. In 
animal models of arterial injury, TF is rapidly induced in the SMCs of the media and 
accumulates in the SMCs of the developing neointima [Merlini et al, 1999; Gertz et al, 
1998; Annex et al, 1995]. 
TF is also abundant m macrophages, and SMCs of atherosclerotic plaques 
[Hatakeyama et al, 1997; Wilcox et al, 1989]. It has also been detected in the extracellular 
matrix and in the acellular lipid rich core in atherosclerotic plaques [Moreno et al, 1996; 
Wilcox et al, 1989]. Induction of TF in human endothelial cells and 
monocyte/macrophages has been extensively studied [Siess et al, 1999; Thiruvikraman et 
al, 1996]. In contrast, little is known about the regulation of its expression in human 
arterial SMC and in the cell and lipid-rich core of the atheromatous plaque. 
LYSOPHOSPHATIDIC ACID (LPA): 
Oxidized LDL is a key factor in the pathogenesis of atherosclerosis. Lysophosphatidic 
acid is formed during mild oxidation of LDL and is the active compound in mildly 
oxidized LDL and minimally modified LDL. It has been found that LP A also accumulates 
in the lipid-rich core of atherosclerotic plaques [Fernandez-Ortiz et al, 1994]. 
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Experimental evidence indicates that the lipid-rich atheromatous core and not the exposed 
collagen is thrombogenic initiator in ruptured plaques [Goetzl et al, 1998]. Our group has 
recently reported that LPA dramatically induces TF expression in RASMCs (TF rnRNA 
was induced eight folds and TF protein and TF total activity were also increased). These 
results indicate that LP A might be a thrombogenic risk factor that plays an important role 
in pathogenesis of atherosclerosis. SMC is known to be one of the important players in 
atherosclerotic lesion development. However, little is known about the regulatory 
mechanisms governing the induction of TF expression by LP A in RASMCs. 
ROLE OF REACTIVE OXYGEN SPECIES IN THE ARTERIAL WALL: 
Reactive oxygen species (ROS) are a family of molecules including molecular oxygen 
and its derivatives produced in all aerobic cells. Many ROS possess unpaired electrons 
and thus are free radicals. These include molecules such as superoxide anion (Ot), 
hydroxyl racial (HO'), nitric oxide (NO'), and lipid radicals. Other reactive oxygen 
species, such as hydrogen peroxide (H202), peroxynitrite (ONOO-), and hypochlorous 
acid (HOCl), are not free radicals per se but have oxidizing effects that contribute to 
oxidant stress [Cai and Harrison, 2000]. 
Reactive oxygen species (ROS) play an important role in many cardiovascular 
pathologies involving inflammatory processes, including atherosclerosis. Several 
pathogenic effects of increased ROS production have been identified. These include the 
oxidation of core lipids of lipoproteins and cell membranes which then modify 
apolipoproteins and other proteins, leading to their recognition by scavenger receptors. 
Similar modifications also influence DNA binding of regulatory proteins in the nucleus. 
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Exposure of cells to ROS induces a local inflammatory response and the release of 
cytokines and growth factors, such as tumor necrosis factor-a., interleukin 1 �, and 
interferon Y. These factors may then provide a positive feedback mechanism, for example 
by stimulating ROS-producing enzymes. Although cells are normally well protected from 
ROS by antioxidant defenses, including oxygen-radical scavenger enzymes, the rate of 
ROS formation can exceed the local antioxidant defense capacity and thus induce oxidant 
stress in arterial cells [Napoli et al, 2001 ]. 
Vascular smooth muscle cell (SMC) hyperplasia and hypertrophy are characteristic of 
atherosclerotic, restenotic, and hypertensive vascular diseases [Ross, 1993]. The net 
balance between proliferation and apoptosis determines the extent of SMC growth. ROS 
can mediate phenotypes in vascular endothelial and smooth muscle cells that may be 
considered both physiological and pathophysiological. Among these are growth, 
apoptosis, and survival. A full understanding of how ROS regulate mitogenesis and 
apoptosis in vascular smooth muscle and endothelial cells will permit the development of 
novel strategies to modify or prevent vascular diseases in which these phenotypes 
predominate [Irani, 2000]. 
7 
II. OBJECTIVES AND HYPOTHESIS 
Tissue factor is the primary initiator of clotting, both normal and pathologic, in a large 
number of clinical settings and animal models [Osterud, 1997]. Tissue factor upregulation 
in atherosclerotic plaque can lead to undesirable vascular thrombosis [Vallet, 2001]. 
Balloon angioplasty of arteries causes endothelial denudation and, as a consequence of 
the exposure of the endothelium to the blood, provokes an instantaneous activation of 
platelets and the coagulation cascade [Gasperetti, 1993 and Hamon, 1995]. Tissue factor 
is rapidly induced in the arterial smooth muscle injured by this procedure [Marmur, 
1993]. An increase in the generation of reactive oxygen species (ROS) by the cells of the 
vascular wall has been observed at sites of balloon injury [Nunes, 1997]. Oxidative stress 
might contribute to the increased expression of proatherosclerotic genes at sites of 
vascular injury, including TF [Taubman, 1997]. Our group has recently reported that LPA 
(a component of oxLDL present within the intima of atherosclerotic lesions) dramatically 
induces TF expression in RASMCs and it has been reported that it can also induce ROS 
release in RASMCs [Schmitz, 2002]. Little is known about the regulation of TF by LPA 
in SMC which is a major player in the process of atherosclerosis. The objectives of this 
study are to elucidate the signal transduction pathways involved in tissue factor induction 
by LP A in SMC. Understanding the mechanism of LP A induction of TF in SMC could 
contribute to proper understanding of atherosclerosis, thrombosis and restenosis after 
vascular procedures. 
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III. MATERIAL AND METHODS 
MATERIALS: 
LPA used in this study was (1 8:1) oleoyl LPA from Avanti Polar Lipids, Inc. 
pertussis toxin, RO-31 , GO-6979, U73122, U73343, PD-98059, UO-1 26, Chelerythrin 
chloride, GF, Resveratrol, SB, Sp, BPB (4-bromophenol bromide), Aristolochic acid, 
BAPTA-AM, and MAFP were from Biomol Research Laboratories Inc. Arachidonic 
Acid, N-acetyl cysteine, sodium formate, desferoxamine, DPI, BEL (bromophenol 
lactone ), thapsigargin, Luminol, and HRP (horse reddish peroxidase) were from Sigma 
Inc. MJ-33 was from Calbiochem Inc. 3H-arachidonic acid was purchased from American 
Radiolabeled Chemical Inc. (ARC). 
TISSUE CULTURE: 
Rat Aorta smooth muscle cells (RASMCs) were prepared from explants of excised 
aortas of rats as described previously [Brock et al., 1985]. RASMCs between passages 
7and 17  were used in these studies. Cells were maintained in Dulbecco's modified Eagle's 
medium containing 10% fetal bovine serum. Cells were made quiescent by incubation in 
serum-free Dulbecco's modified Eagle's medium for 48 h prior to the addition of LPA or 
other agonists or drugs as described previously [Schecter et al., 1997 and Penn et al ., 
1999]. Human smooth muscle cells (HASMCs) were purchased from BioWhittaker, A 
Camprex Company. HASMCs between passages 4 and 7 were used. 
9 
NORTHERN BLOT ANALYSIS FOR DETECTION OF RASMCS TF MRNA: 
Total cellular RNA was isolated by using TRizol reagent (Gibco BRL.) according to 
the manufacturer's instructions. Total RNA (5-6 µg) was subjected to denaturing 
electrophoresis in formaldehyde/agarose gels. RNA was blotted onto Hybond™-N; nylon 
(Amersham) membranes and hybridized with radiolabeled cDNA probes [Virca et al., 
1990]. A 685-bp EcoRI fragment of rat TF cDNA (GenBank™ accession number 
U0761 9) was a gift from Dr. Mark B. Taubman (Mount Sinai School of Medicine, New 
York) and was used to detect TF mRNA, whereas glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA was used as an internal control. 
NORTHERN BLOT ANALYSIS FOR DETECTION OF RASMCS EGR-1 AND 
HASMCS TF MRNA: 
Total cellular RNA was isolated by using TRizol reagent (Gibco BRL.) according to 
the manufacturer's instructions. RNA samples (8 µg per lane) were separated by 
electrophoresis through 1 .2% agarose gels after denaturation of the RNA with glyoxal and 
dimethylsulfoxide [Morawietz et al., 1999]. RNA was transferred with 20x SSC buffer to 
Hybond-N nylon membranes (Amersham Life Science Inc). RNA was then hybridized 
with radiolabeled cDNA probes (641 bp EcoRI fragment of human TF cDNA or 1 .5 kb of 
mouse Egr-1 ) in: 1 mol/L NaCl, 1 % SDS, 10% dextran sulfate, and 100 µg/mL 
denatured salmon sperm DNA at 65°C for 16 hours. The membranes were washed twice 
for 15 minutes with 2xSSC, 0.1 % SDS at 60°C and once for 15 minutes with 0.2xSSC, 
0. 1 % SDS at 55°C. 
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ADENOVIRUS CONSTRUCTS AND ADENOVIRAL INFECTION OF RASMCS: 
Adenoviruses encoding mouse PKC isotypes (6, c, or t) were constructed as 
previously described [Ohba et al., 1998 and Matsumoto et al., 2001]. The adenoviral 
vectors were amplified in 293 cells to obtain a high titre of the virus before infecting 
RASMCs. The cells were infected by vectors expressing the following proteins : Lac-Z 
( control), wild type PKC e (PKC e-wt), kinase deficient PKC e (PKC e-kd), wild type 
PKC o (PKC o-wt), dominant negative PKC o (PKC o-dn), PKC t (PKC t-wt), and 
dominant negative PKC t (PKC t-dn) for 24 h. the cells were then starved for 48 hours 
and the stimulated by LPA for 1.5 h or unstimulated. 
WESTERN BLOT ANALYSIS: 
Total cellular proteins were obtained from RASMCs grown in 100-mm dishes. At the 
end of each incubation, cell lysates were washed twice with PBS. Combined floating and 
attached cells were lysed by sonication for 20 s on ice in W estem blot lysis buffer 
(50 mM Tris-HCl, pH 6.8, 8 M urea, 5% J-mercaptoethanol, 2% SDS, and protease 
inhibitors). After addition of 4x SDS sample buffer and incubation at 65 °C for 15 min, 
samples were subjected to SDS-polyacrylamide gel 10% electrophoresis and transferred 
to a polyvinylidene fluoride membrane (Immobilon-P, Millipore). The membranes were 
then probed with antibodies against Egr-1 (Cl 9), CREB, P-CREB, MEK, and P-MEK 
(Snta Cruz) followed by a 1 :3000 dilution of a peroxidase-labeled secondry antibody. The 
signal was visualized by ECL-Plus (Amersham Biosciences) as described previously [Xu 
et al., 1999]. 
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ELECTROPHORETIC MOBILITY SHIFf ASSAYS: 
Cell lysates were prepared from from RASMCs grown in 100-mm dishes. At the end 
of each incubation, cell lysates were washed twice with PBS. Combined floating and 
attached cells were lysed by sonication for 20 s on ice in luciferase assay lysis buffer 
(Promega). Oligonucleotides containing a prototypic Sp 1 site, an AP-1 site, and NFKB 
site were obtained from Promega Corp. An oligonucleotide containing a prototypic EGR-
1 site was obtained from Operon Technologies (Alameda, CA). Oligonucleotides were 
radiolabeled using [32P]dCTP (Amersham Corp.) as described [Oeth et al., 1994]. Gel 
shift assays were performed as follows: cell lysates ( 4-5 µg) were incubated with 
radiolabeled DNA probes (about l Ong; 1 )(106 cpm) for 20 min at room temperature in a 
20-µl binding reaction containing 20 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM EDTA, 
5% glycerol, 1 mM dithiothreitol, 1 mg/ml bovine serum albumin, 0.1 % Nonidet P-40, 
and 12.5 µg/ml poly (dl-dC). Protein-DNA complexes were separated from free DNA 
probe by electrophoresis through 6% nondenaturing acrylamide gels (Novex, San Diego, 
CA) in 0.5 xTris borate-EDTA. For competition and antibody supershift experiments, 
binding reactions were incubated with unlabeled double-stranded oligonucleotides (50 
molar excess) or monospecific antibodies for 20 min before the addition of the 
radiolabeled oligonucleotide. Anti-EGR-1 (C19),anti-SRF, and anti CREB antibodies 
were obtained from Santa Cruz Biotechnology, (Santa Cruz, CA). 
TRANSIENT TRANSFECTION ASSAY: 
RASMCs were cultured in 60-mm dish 24 h prior to transfections. SuperFect 
reagent from Qiagen was used in transfeting the cells in accordance with the 
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manufacturer's recommendations. One set of RASMCs was transfected with a plasmid 
containing the wild type TF promoter cloned upstream of the luciferase reporter gene 
(5µg) [pTF (-258)]. Another set of cells was cotransfected with the same plasmid [pTF (-
258)] and another plasmid expressing Lacz (pcDNA3.l/LacZ) (5µg). A third set of cells 
was cotransfected with pTF (-258) and another plasmid expressing Egrl (pSVKrox-24) (5 
µg) which was kindly provided by P. Charnay [LeMaire et al. , 1990]. Cells were starved 
for 48 hours before assaying luciferase activity. Luciferase activity was determined using 
the Luciferase Assay System (Promega) and ML2250 luminometer (Dynatech). 
DELETION ANALYSIS AND FUNCTIONAL ANALYSIS OF THE EGR-1 
PROMOTER: 
A series of transfection studies have been conducted to determine the LP A primary 
response regions in the Egrl promoter. According to the published rat Egrl promoter 
sequence, a set of oligonucleotides have been synthesized as primers to clone a series of 
Egrl promoter regions with selected deletions by PCR techniques using the rat genomic 
DNA. These derivatives were cloned upstream of the luciferase reporter gene in the 
plasmid pGL2. LPA responsiveness of the promoter region of the Egrl gene was 
evaluated by transiently transfecting RASMCs with the deleted Egrl promoter constructs 
(hooked to a luciferase reporter gene) and subsequently treating these cells with LP A 
(25µM) for 3 hours after starving it for 48 hours. The construct pGL2/Egrl (-140/+21) 
contains a luciferase reporter gene driven by the rat Egrl promoter fragment -140/+21 
which have 2 SRE and 2 CRE areas. To perform Functional analysis of the Egr-1 
promoter, We constructed a plasmid having the 2 SRE areas mutated [pGL2/Egrl (-
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140/+21)dmSRE] and another plasmid having the 2 CRE areas mutated [pGL2/Egrl(-
140/+2 l)dmCRE]. RASMCs were transiently transfected by those constructs, starved for 
48h and then either untreated or stimulated with LP A (25 µM) for 3 hours. 
ROS RELEASE DETECTION: 
A variety of oxygen radicals, including superoxide anion and the hydroxyl radical, 
as well as hydrogen peroxide are potential mediators of luminal-dependent 
chemiluminescence Luminol ( amino-2,3-dihydro-1,4-phthalazinedione) undergoes a 
dioxygenation reaction in the presence of reactive oxygen species to yield a cyclic 
peroxide that disintegrates to yield the electronically excited aminophthalate anion HRP 
(horseradish peroxidase) is used to enhance the the chemiluminescence signal [ Allen, 
1982]. Rat Aorta smooth muscle cells (RASMC) were grown in Dulbecco's minimal 
essential medium (DMEM) containing 10% fetal bovine serum. Cells were serum starved 
for 24 hours in serum-free DMEM prior to use for experiments. ROS were detected by 
the luminal and HRP-dependent chemiluminescence assay [Goldman et al, 1998]. 
Serum-starved cells were rinsed with PBS, trypsinized, suspended in Hanks balanced salt 
solution (HBSS), and were washed twice with HBSS. Cells (1x106) were incubated in a 
test tube (75x12 mm, Sarstedt no. 55.476) in 0.5 ml HBSS · containing 0.2% fatty acid­
free BSA, 100 µM luminol, and 0.5 unit of HRP at 37 °C for 10 min. Cells were then 
placed in the luminometer and LP A (25 µM) was added at time 0. Chemiluminescence 
was recorded immediately at 1 minute intervals. 
14 
DETERMINATION OF 3H-ARACHIDONIC ACID {3H-AA) RELEASED FROM 
PRELABELED RASMC EXPOSED TO LYSOPHOSPHATIDIC ACID (LPA)� 
To determine the effect of LPA on AA release in RASMC, cells were seeded into six 
well culture plates at a density of 3 x 105 cells/well and grew them to 75% confluence. 
Release of 3H-AA into the medium was determined as described previously [Tithof et al, 
1998]. Briefly, the cells were labeled with 3H-AA for 24 h. Release of AA was 
determined by incubating cells with compounds in Hank's Balanced Salt Solution with 
0.1 % albumin to inhibit reacylation and metabolism of released AA. Therefore, the data 
reflect cumulative deacylation from membrane phospholipids. 
When the cells were 90 % confluent, release of 3H-AA was determined after 
exposure to LP A (25 µM) for 1 h. At the end of the incubation period, the medium was 
collected into scintillation vials containing: xylene, 2,5-diphenyloxazole, 
polyoxyethylene, octyl phenol, Bis-MSB, and oleic acid. The radioactivity was 
determined by scintillation counting. Radioactivity in the cellular fraction was also 
determined, and 3H-AA release was expressed as a percentage of total cellular 
radioactivity. 
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IV. Results 
INDUCTION OF TF MRNA BY LPA: 
LP A significantly increased TF mRNA in quiescent RASMCs in a concentration 
dependent manner with maximal accumulation at 25 to 50 µM LPA [Figure 1 (figures: 1-
45 are located in the appendix)]. Maximal levels ofTF mRNA were observed at 1.5-2h of 
LP A stimulation. The increased accumulation of TF mRNA induced by LP A was 
transient and declined significantly between 4 and 8 hours (figure 2)_. 
IDENTIFICATION OF THE TRANSCRIPTION FACTORS THAT BIND TO 
THE RAT TF PROMOTER UPON INDUCTION BY LPA: 
Our group's preliminary transfection data suggest that the region from -258 to + 106 
of the Rat TF promoter is important for the TF gene induction by oxLDL. This area 
contains severaltranscription factor binding sites (two AP-1 sites, one NFrl3 site, four 
Spl sites and one Egr-lsite). Electrophoretic mobility shift assays (EMSA) were used to 
examine whether binding activities of the above mentioned transcription factors were 
induced by LP A. Radiolabeled oligonucleotides containing the above mentioned sites in 
the rat TF promoter were incubated with cell lysates from quiescent untreated cells or 
cells treated with LP A for the indicate times. As shown in Fig.3 (C), at the Egr-1 site, in 
addition to the slower migrating protein-DNA complex (complex I) which remains 
unchanged during treatment, an increase in the signal intensity of another faster 
migrating protein-DNA complex (complex II) was induced by LPA. In contrast, no 
detectable changes were observed in Spl, NFrl3, or Apt binding activities (figure 3 A, B, 
D). The identity of this complex (complex II) was confirmed by using an antibody that 
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specifically recognizes the transcription factor Egrl. The Egrl complex ( complexll) 
observed in LP A-stimulated cells [figure 4 (lane 2)] was abolished by pre-incubation of 
the RASM cell lysate with the Egrl specific antibody, indicating that the induced band is 
Egr-1 complex. 
EGRl MRNA IS INDUCED BY LPA: 
LP A (25 µM) significantly increased Egrl mRNA in quiescent RASMCs. 
Maximal levels of Egrl mRNA were observed at about 35-50 minutes of LPA 
stimulation. The increased accumulation of TF mRNA induced by LP A was transient and 
decreased significantly after about 3.5 hours (figure 5). 
EGRl TRANSACTIV ATES THE TF PROMOTER ACTIVITY: 
RASMCs were trasfected with a plasmid containing the wild type TF promoter 
cloned upstream of the luciferase reporter gene [pTF (-258)]. Another set of cells was 
cotransfected with the same plasmid and another plasmid expressing Lacz 
(pcDNA3.1/LacZ). A third set of cells was cotransfected with both pTF (-258) and 
another plasmid expressing Egrl (pSVKrox-24). The results show increased fold of 
luciferase activity in the cells cotransfected with both pTF/-258 and pSVKrox-24 
compared to the other two sets indicating that Egr-1 transactivates the TF promoter, 
suggesting that Egrl is a transcriptional activator of the TF gene in RASMCs (figure 6). 
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INCREASED EGRl TRANSCRIPTIONAL BINDING ACTIVITY IS TRANSIENT 
AND IS DUE TO DE NOVO PROTEIN SYNTHESIS: 
To investigate if increased Egr-1 binding activity induced by LP A is due to de novo 
protein synthesis or activation of pre-existing Egr-1 protein by post -translational 
modification, levels of Egrl protein in cell lysates from quiescent and LPA-stimulated 
RASMCs were assessed by western blotting using an Egrl-specific antibody. As shown 
in figure 7, Egrl protein was not detectable in quiescent cells. However, Egrl protein 
expression was transiently induced following stimulation with LP A and expression level 
increased after about 35-50 minutes and then declined. 
LOCALIZATION OF THE LPA-RESPONSIVE REGION IN THE EGRl 
PROMOTER: 
A series of transfection studies was conducted to determine the LP A primary response 
regions in the Egrl promoter. Using the published mouse Egrl promoter sequence, a set 
of oligonucleotides were synthesized as primers to clone a series of rat Egrl promoter 
regions with selected deletions by PCR techniques using the rat genomic DNA. LP A 
responsiveness of the promoter region of the Egrl gene was evaluated by transiently 
transfecting RASMCs with the deleted Egrl promoter constructs which were inserted 
upstream of the luciferase gene. The cells were subsequently treated with LP A (25 µM) 
for 3 hours after starvation for 48 hours. Four-fold induction by LPA was observed until 
deletions reached -140 bp. Further deletion resulted in a significant loss of activity (figure 
8, 9). Sequence analysis revealed that this area of the Egrl promoter contains two SRE 
( serum response elements) and two CRE ( cyclic AMP response elements) sites. 
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FURTHER CHARACTERIZATION OF THE REGULATORY ELEMENTS IN 
THE EGRl PROMOTER (SRE AND CRE ARE INVOLVED IN MEDIATING 
LPA INDUCTION OF THE EGR-1 PROMOTER ACTIVATION: 
Transcriptional regulation of gene expression is mediated through DNA binding 
proteins, termed transcription factors. Response elements are the recognition sites of 
certain transcription factors. Most of them are located within 1 kb from the 
transcriptional start site. The Serum Response Element (SRE) present in the promoter 
region of several genes, including Egr-1, requires the binding of SRF ( serum response 
factor) to activate expression of the gene downstream. [Lamb et al., 1996] . Another 
response element in the Egr-1 promoter is the cyclic AMP response element (CRE) which 
binds the transcription factor cyclic AMP response element binding protein (CREB) 
[Silva et al, 1998]. 
EMSA (electrophoretic mobility shift assays) were performed by incubating 32P­
labeled oligonucleotides containing SRE and CRE sites with cell lysates from untreated 
and LPA-stimulated RASMCs for various times. SRE binding activity was transiently 
induced, peaked between 7 and 15 minutes and decreased to background level at about 30 
minutes (figure 10). Similarly, CRE binding activity was' induced at about 10 minutes 
(figure 11). To determine whether the binding of the cell lysates to these regions of the 
Egrl promoter was specific, competition studies using 50-fold molar excess of unlabeled 
SRE and CRE oligonucleotides were performed. Both SRF and CREB binding activities 
were completely blocked (no induced complex was formed), indicating the specificity of 
these bindings [Figure 12, 13 (lanes 5, 6)]. When radiolabeled oligonucleotides 
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containing mutated SRE and mutated CRE were also incubated with cell lysates from 
untreated and LPA-stimulated RASMCs for 15 and 10 minutes respectively. As shown in 
Figure 12 and 13, Both mutated SRE and CRE sites failed to bind to corresponding 
transcriptional factor confiming again the specificities of these binding activities observed 
with wild type SRE and CRE. Further confirmation was achieved by using antibodies that 
specifically recognize SRF and CREB. The protein-DNA complexes observed using 
LPA-stimulated cells were supershifted by pre-incubation of the RASMC lysates with 
these specific antibodies (fig12, 13). 
FUNCTIONAL ANALYSIS OF THE EGRl PROMOTER CONFIRMED THE 
INVOLVEMENT OF SRE AND CRE IN TURNING ON THE EGRl PROMOTER 
BY LPA: 
The construct pGL2/Egrl (-140/+21) contains a luciferase reporter gene driven by 
the fully active rat Egrl promoter fragment -140/+21 which contains two SRE and two 
CRE sites. We also constructed a plasmid having the two SRE sites mutated [pGL2/Egrl 
(-140/+21) dmSRE] and another plasmid having the two CRE sites mutated 
[pGL2/Egrl(-140/+21) dmCRE]. RASMCs were transiently transfected with those 
constructs, starved for 48h and then either untreated or stimulated with LP A (25 µM) for 3 
hours. The results revealed that the double SRE and double CRE mutations reduced the 
LPA induction of the Egrl promoter from 2.71 -fold to 1 .1 7-fold and 1 .11-fold 
respectively (figure 14). These data together with the EMSA results indicates that both 
SRE and CRE sites are required for mediating LP A-induction of Egr-1 which ultimately 
regulate TF expression. 
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PERTUSSIS TOXIN SENSITIVE G-PROTEIN, PKC, PKD, AND MAPK ARE 
INVOLVED IN LPA-INDUCED TF AND EGRl SIGNALING PATHWAYS IN 
RASMCS: 
Several LP A receptors have been cloned and all of them have been identified as G 
protein coupled receptors [Goetzl and An, 1998].To define the intracellular signaling 
pathways involved in LPA-induced TF gene expression, RASMCs were preincubated 
with the following drugs: pertussis toxin (Goo. inhibitor), UO-126, PD98059 (MAPK 
inhibitors), SB-203580 (p38 inhibitor), GF-109, RO-31, chelerethrine chloride (pan-PKC 
inhibitors),GO-6976 (a, (3 PKC inhibitor), Sp-600125 (JNK inhibitor), U-73122 (PLC 
inhibitor), U73343 (negative control for U73122) and Resveratrol (PKD inhibitor). 
Northern blot analyses revealed that LP A-induction of TF and Egrl mRNA accumulation 
were blocked by PTX (Goo. inhibitor), indicating the involvement of a PTX-sensitive G­
protein (Goo.) in the signaling pathway mediating LP A induction of TF and Egrl gene 
expression. It was also found that LPA-induced TF and Egrl mRNA accumulation were 
blocked in the cells pretreated with UO-126, PD98059 (MAPK inhibitors), GF-109, RO-
31, chelerethrine chloride (PKC inhibitors) and Resveratrol (PKD inhibitor) ,whereas, 
they were not blocked by GO6976, SB-203580 (p38 inhibitor), Sp-600125 (JNK 
inhibitor) and U73343, {PLC inhibitor). These results suggest that MAPK, PKC and PKD 
are involved in the signaling pathway of LPA-induced TF and Egrl gene expression 
whereas PKC a, (3, p38, JNK and PLC are not involved (figures 15-18). 
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PKCc IS INVOLVED IN LPA-INDUCTION OF TF MRNA EXPRESSION: 
The above mentioned data suggest that some PKC isofonns ( except for a, {j) are 
involved in the signaling pathway of LP A-induced TF and Egrl mRNA expression. PKC 
exists as a family composed of at least 10 isofonns. They are classified into three major 
groups [conventional PKC isofonns (a, /jl, (fl, and 'Y), novel PKC isofonns (o, e, r,, and 
8) and atypical PKC isofonns (t and A) (Chiu and Rozengurt, 2001 ). The possible roles of 
o, e , and t isofonns on LP A induction of TF m.RNA expression in RASMS have been 
examined. An adenovirus vector system which allows high expression of the genes 
encoding for these proteins in almost all the cells infected for at least 24 hours (kindly 
provided by T. Kuroki) was used. RASMCs were infected by vectors expressing the 
following proteins : Lac-Z ( control), wild type PKC e (PKC e-wt), kinase deficient PKC e 
(PKC e-kd), wild type PKC o (PKC o-wt), dominant negative PKC o (PKC o-dn), PKC t 
(PKC t-wt), and dominant negative PKC t (PKC t-dn) for 24 h. the cells were starved for 
48 hours and then stimulated by LPA for 1.5 h or unstimulated. Total RNA was harvested 
and Northern blot analyses were performed. TF mRNA was only blocked in cells infected 
with the adenovirus expressing kinase deficient PKC f suggesting that PKC f is involved 
in LP A-induced TF m.RNA expression, whereas, PKC o and PKC t are not involved in 
this signaling pathway (figures 19, 20). 
LPA STIMULATES ROS RELEASE IN RASMCS: 
Reactive oxygen species (ROS) in specified amounts play an important role in 
normal metabolic and signalling processes. However, excess ROS can cause severe 
cardiovascular damage. ROS cause various types of damage to ion channels and pumps 
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and this damage is associated with vascular diseases such as atherosclerosis and 
hypertension (Walia et al, 2003). To determine whether LP A increases ROS release in 
RASMCs, serum-starved RASMCs were incubated with luminal (100 µM) and HRP (see 
material and methods for details). Low chemiluminescence was detected in the absence of 
LPA. Addition of LP A (25 µM) caused a rapid and marked increase in the 
chemiluminescence signal within a couple of minutes to return to the basal level after 
about 5 to 6 hours (figure 21). To determine if the chemiluminescence signal was 
generated from ROS, cells were pre-treated with N-acetyl cysteine (a general antioxidant) 
in a concentration of 10 mM for 30 minutes and then treated with LP A (25 µM). Figure 21 
shows that NAC diminishes the LPA-stimulated chemiluminescence signal, indicating 
that the chemiluminescence signal is a valid measure for ROS release. These results 
indicate that LP A stimulates ROS release in RASMCs. 
ANTIOXIOXIDANTS BLOCK LPA INDUCTION OF TF MRNA: 
The above mentioned data indicates that LP A induces TF mRNA expression and 
at the same time stimulates ROS release. To determine whether LP A-induced ROS 
release is also involved in TF mRNA induction, quiescent RASMCs were stimulated with 
LPA (25 µM) for 1.5 h alone or after preincubation with the following antioxidants: 
sodium formate [Na F. (specific blocker for free hydroxyl radicals release)] in a 
concentration of 100 mM for 24 h, N-acetyl cysteine [NAC (general antioxidants)] in a 
concentration of 10 mM for 30 min., desferoxamine mesylate (hydrogen peroxide release 
blocker) in a concentration of 50 mM for 30 min., and DPI [ diphenyleneiodonium 
chloride (specific blocker for free oxygen radical release)] in a concentration of 25 µM 
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for 30 min. Northern blot analysis revealed that LPA-induction of TF mRNA was 
blocked in the cells pre-treated with sodium formate, NAC and DPI suggesting that ROS 
is involved in LPA induction ofTF mRNA (figure 22). 
MAPK IS INVOLVED, BUT, PTX AND PKC ARE NOT INVOLVED IN LPA­
INDUCTION OF ROS RELEASE IN RASMCS: 
In the above mentioned data, PTX, PKC, and MAPK were shown to be involved 
in LP A-induction of TF mRNA. ROS release was measured in quiescent RASMCs after 
stimulation with LPA (25µM) alone or after pretreatment with PTX (1 20ng/ml) for 16  h, 
GF (lOµM), or UO126 (lOµM) (for 30 minutes each) to determine if the same G 
proteins-coupled receptors signaling pathway (involved in LP A-induced TF mRNA) is 
also involved in LPA-stimulated ROS release. As shown in figures 23, 24, and 25, PTX 
(Gai inhibitor) and GF (pan-PKC inhibitor) failed to block this induction. Only UO126 
(MAPK inhibitor) was effective. These data suggests that LP A-induction of ROS release 
may involve an alternative signaling pathway which does not involve PTX-sensitive G­
protein. 
LPA STIMULATES AA RELEASE IN RASMCS: 
Arachidonic acid (AA) is a polyunsaturated fatty acid present in cell membranes that 
modulates diverse physiologic and pathologic responses. These effects are primarily 
mediated by its metabolic products. Their effects, which depend on the nature of 
compounds, principally concern inflammation and thromboregulation (Marcus, 1994 ). It 
is well known that several transduction pathways are activated by LP A including 
arachidonic acid release (Moolenaar, 1995). To determine whether LP A increases AA 
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release in RASMCs, the cells were labeled with 3H-AA for 24 h. Release of AA was 
determined by incubating cells with LPA (25 µM) in Hank's Balanced Salt Solution with 
0.1 % albumin to inhibit reacylation and metabolism of released AA. When the cells were 
90 % confluent, release of 3H-AA was determined after exposure to LP A (25 µM) for 1 
h. At the end of the incubation period, the medium was collected into scintillation vials 
and the radioactivity was determined by scintillation counting. Radioactivity in the 
cellular fraction was also determined, and 3H-AA release was expressed as a percentage 
of total cellular radioactivity. Figure 26 shows a time course for the release of AA in 
RASMCs upon stimulation by LP A. 
AA INDUCES TF MRNA: 
AA is known to enhance the TF expression in mononuclear cells (Cadroy et al, 
1998). To determine whether AA induces TF mRNA in RASMCs, quiescent RASMCs 
were stimulated with AA (I OµM) for different periods of time. Northern blot analysis was 
performed. Maximal levels of TF mRNA were observed after about 1.5 h of LP A 
stimulation. The increased accumulation of TF mRNA induced by LP A was transient and 
decreased to basal level in 8 hours (figure 27). 
AA STIMULATES ROS RELEASE IN RASMCS: 
It was reported that AA may play an essential part in activation of the enzyme 
NADPH oxidase, which is responsible for the generation of superoxide anion by 
neutrophils (Dana et al, 1994; Henderson et al, 1993; and Badwey et al, 1981). To 
determine whether AA increases ROS release in RASMCs, serum-starved RASMCs were 





AA. Addition of AA (lOµM) caused ·a rapid increase in the chemiluminescence signal 
within a couple of minutes. (figure 28). To determine if the chemiluminescence signal 
was generated from ROS, cells were pre-treated with N-acetyl cysteine (a general 
antioxidant) and then treated with AA (l0µM). Figure 28 shows that NAC diminished the 
AA-stimulated chemiluminescence signal. Together, these results indicate that AA can 
stimulate ROS release in RASMCs. 
ANTIOXIOXIDANTS BLOCK AA INDUCTION OF TF MRNA IN RASMCS: 
The data presented above indicates that AA induces TF mRNA and at the same 
time stimulates ROS release in RASMCs. To determine whether AA-induced ROS 
release is also involved in TF mRNA induction, quiescent RASMCs were stimulated with 
AA (50µM) for 1 .5 h alone or after pre-treatment with the following antioxidants: sodium 
formate [Na F. (specific blocker for free hydroxyl radicals release)] in a concentration of 
lO0mM for 24h, N-acetyl cysteine [NAC (general antioxidants)] in a concentration of 10 
mM for 30 min., desferoxamine mesylate (hydrogen peroxide release blocker) in a 
concentration of 50 mM for 30 min., and DPI [ diphenyleneiodonium chloride (specific 
blocker for free oxygen radical release)] in a concentration of 25 µM for 30 min. 
Northern blot analysis revealed that AA-induction of TF mRNA was blocked in the cells 
pre-treated with sodium formate, and DPI, suggesting that ROS is involved in AA 
induction of TF mRNA (figure 29). 
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PHOSPHOLIPASE A2 (PLA2) IS INVOLVED IN RELEASING AA FROM. 
MEMBRANE PHOSPHOLIPIDS: 
PLA2 cleaves phospholipids at the sn-2 position to produce AA (Van Corven et al, 
1989). Several different isoforms of PLA2 have been described [Murakami and Kudo, 
2002] . To investigate whether PLA2 is involved in releasing AA from membrane 
phospholipids in RASMCs upon stimulation by LPA, quiescent RASMCs were 
stimulated with LP A (25 µM) for 1.5 h alone or after pretreatment with the following 
PLA2 inhibitors: MAFP (10 µM), ARA (aristolochic acid, 10 µM), BPB (10 µM), Bel (10 
µM), and MJ33 (10 µM), each for 30 minutes. It was found that LPA-induction of TF 
mRNA was blocked in the cells pre-treated with ARA, Bel, and MJ 33, suggesting that at 
least some of PLA2 isoforms are involved (figure 30). The same PLA2 inhibitors also 
blocked ROS release in RASMCs (figure 31, 32, 33) suggesting that LPA-induction of 
ROS release in RASMCs involves PLA2-mediated AA release. 
ANTIOXIDANTS DO NOT BLOCK LP A-INDUCTION OF MAPK SUGGESTING 
THAT LPA-INDUCED ROS RELEASE IS DOWNSTREAM OF MAPK 
INDUCTION IN RASMCS: 
The above mentioned data (figure 25) suggests that MAPK is involved in LPA­
induction of ROS release in RASMCS. To further confirm that MAPK acts upstream of 
ROS, quiescent RASMCs were stimulated with LPA (25µM) for 3 minutes alone or after 
preincubation with the following antioxidants: sodium formate [Na F. (specific blocker 
for free hydroxyl radicals release)] in a concentration of lOOmM for 24h, N-acetyl 
cysteine [NAC (general antioxidants)] in a concentration of 10 mM for 30 mm., 
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desferoxamine mesylate (hydrogen peroxide release blocker) in a concentration of 50 mM 
for 30 min., and DPI [diphenyleneiodonium chloride (specific blocker for free oxygen 
radical release)] in a concentration of 25 µM for 30 min. Cell lysates were collected and 
Western blot analysis was performed. Figure 34 shows that the anti-oxidants, which were 
shown to block ROS production, do not block LP A-induction of MAPK suggesting that 
LP A-induced ROS acts downstream ofLPA-induced MAPK activation or independent of 
MAPK activation. 
U0126 BLOCKS AA-INDUCTION OF ROS RELEASE CONFIRMING THAT 
ROS ACTS DOWNSTREAM OF MAPK: 
Serum-starved RASMCs were incubated with luminol and HRP. They were then 
stimulated with AA (lOµM) alone or after pre-incubation with U0126 (lOµM) for 30 
minutes. Addition of AA (l0µM) caused a rapid increase in the chemiluminescence 
signal within a couple of minutes. U0126 pretreatment diminished AA-stimulated 
chemiluminescence signal (figure 35) confirming that MAPK mediates AA-induction of 
ROS release. 
CALCIUM MOBILIZATION IS INVOLVED IN LPA-INDUCTION OF TF 
EXPRESSION: 
It is well known that LP A induces calcium mobilization (J alink et al., 1995 and 
AN et al., 1 998). A previous study also indicated that calcium is required for ROS release 
in kerationocytes (Goldman et al., 1998). To determine whether calcium mobilization is 
involved in the LP A-induced TF mRNA pathway, quiescent RASMCs were stimulated 
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with Thapsigargin alone [endoplasmic reticulum Ca ATPase inhibitor (10 µM for 1 .5 h)], 
with LPA alone (25 µM for 1.5 h) or after preincubation with BAPTA-AM [intracellular 
calcium chelator ( 40 µM for 30 minutes)]. Northern blot analysis was performed. The 
results show that thapsigargin alone was able to induce TF mRNA. At the same time, 
BAPTA-AM was able to block LPA-induced TF mRNA suggesting that calcium 
mobilization is involved in induction ofTF mRNA by LPA (figure 36). 
CALCIUM MOBILIZATION IS INVOLVED IN LPA-INDUCTION OF ROS 
RELEASE: 
To determine whether calcium mobilization is also involved in LPA-induced ROS 
release, serum-starved RASMCs were incubated with luminol and HRP. They were then 
stimulated with LPA (25µM) alone or after pre-incubation with BAPTA-AM (40µM) for 
30 minutes. Addition of LP A (25 µM) caused a rapid increase in the chemiluminescence 
signal within a couple of minutes. BAPTA-AM pretreatment diminished the LP A­
stimulated chemiluminescence signal (figure 37), suggesting a role for calcium 
mobilization in LPA-induction of ROS release. 
CALCIUM MOBILIZATION IS ALSO INVOLVED IN BOTH AA-INDUCED TF 
MRNA AND AA-INDUCED ROS RELEASE:  
We also determined whether calcium mobilization is involved in AA-induction of 
TF mRNA and ROS release. The same previous 2 experiments ( determining the relation 
between calcium mobilization and both TF mRNA and ROS release induction by LP A) 
were repeated exchanging AA (50µM) for LPA (25µM). Similar results were observed, 
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suggesting that calcium mobilization is also involved in AA-induction of TF mRNA and 
ROS release in RASMCs (figure 38, 39). 
USE OF HUMAN AORTA SMOOTH MUSCLE CELLS (HASMCS): 
Northern blot analyses were performed using Quiescent HASMCs to see whether 
the results obtained by using RASMCs can be reproduced in human cells. LP A 
significantly increased TF mRNA in quiescent HASMCs in a concentration dependent 
manner with maximal accumulation at SµM LPA (compared to 25-S0µM in RASMCs), 
indicating that HASMCs are more sensitive to LP A ( compare figure I and figure 39). The 
results also indicate that responses to pertussis toxin and kinases inhibitors were similar, 
whereas the human cells were responding mainly to antioxidants blocking the release of 
free oxygen radicals (figures 40-45) (RASMCs responded also to antioxidants that block 
the release of free hydroxyl radicals). 
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V. DISCUSSION 
Tissue Factor is the principal initiator of blood coagulation [Morrissey, 1997]. 
Upregulation of intravascular TF occurs in many models of inflammation and stress, and 
its upregulation is important in pathologic thrombotic events [Kibbe et al., 2003]. LPA is 
a component of oxLDL which has been shown to accumulate in human atherosclerotic 
plaques [Seiss et al., 1999]. Our group has recently reported that LP A markedly induces 
TF mRNA, TF protein , and TF surface activity in RASMCs [Cui et al., 2003]. It has also 
been reported that LPA induces ROS release in RASMCs [Schmitz, 2002]. The 
generation of ROS, which act as a signaling molecule in the vascular system, is enhanced 
in response to injury and has been associated with a procoagulant state and the 
progression of atherosclerotic disease [Berk, 1999; Kunsch and Medford, 1999; and Ruef 
et al., 1999]. The results of our study provide a link between these observations and 
contribute to dissecting the relevant signaling pathways involved. 
The importance of oxidized LDL (OxLDL) in atherogenesis is currently well 
appreciated [Kita et al., 2001]. LPA is formed during mild oxidation of LDL and it was 
reported to be a major component of both the lipid core and the intima of atherosclerotic 
lesions [Seiss et al., 1999]. LPA may play a role in the early phase of atherosclerosis by 
inducing monocyte adhesion to the vascular endothelium, as well as in the late phase by 
triggering platelet activation and intra-arterial thrombus formation upon rupture of the 
atherosclerotic plaque. Moreover, LP A, by stimulating the proliferation of fibroblasts 
and by enhancing the survival of inflammatory cells, is likely to play a central role in the 
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excessive fibro-proliferative and inflammatory response to vascular injury that 
characterizes the progression of atherosclerosis. Furthermore, LP A can cause the 
phenotypic de-differentiation of medial smooth muscle cells that leads to the formation of 
the neointima [reviewed in Seiss, 2002]. Our study demonstrates that LPA significantly 
increases TF mRNA in both RASMCs and HASMCs. These data indicate another 
important aspect of the athero- and thrombogenic actions of lysophosphatidic acid. 
A recent study of our group indicated that LPA-induced increase in TF mRNA 1s 
controlled at the transcriptional level [Cui et al., 2003]. The transcriptional regulation of 
TF expression appears to be both cell type-specific and stimulus-specific [ reviewed in 
Bavendiek et al., 2002 and Mackmam, 1997]. Functional studies of the human TF 
promoter in various cell types identified two promoter regions implicated in TF gene 
expression. The first region, termed the LPS-response element (LRE), contains two AP-1 
(activator protein-I )  and one NF-KB (nuclear factor KB)-like binding sites. The LRE 
mediates inducibility of the TF promoter in response to pro-inflammatory stimuli ( e.g. 
IL-1/3 and TNFa), LPS, and PMA. The second region, the serum response region (SRR), 
contains three Egr-1 binding sites. This region mediates the induction of TF gene 
expression via Egr-1 in response to serum, PMA, shear stress, LDL, hypoxia, vascular 
endothelial growth factor, and LPS. A distal enhancer (-227 to -1 72) containing two AP-1 
sites and an NF-KB site mediates induction of the human TF promoter in monocytic cells 
and endothelial cells. Similarly, two AP-1 sites (-220 to -200) regulate induction of the 
murine TF promoter in fibroblast-like cells. Proximal enhancers in the human (-109 to -
59) and rat (-103 to -80) TF promoters containing Egr-1 and Sp 1 sites mediate induction 
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in epithelial-like cells and vascular smooth muscle cells, respectively. Our results indicate 
that LP A significantly induces TF and Egr-1 mRNA in RASMCs. Our western blot 
analysis and gel-shift results indicate that LP A induces immediate and de novo Egr-1 
mRNA and protein synthesis. Importantly, our data demonstrate that LP A induces the 
binding activity of Egr-1 to the TF promoter. These results suggest that LP A-induction 
of TF gene expression in RASMCs is mediated by the transcription factor Egr-1. 
Egr-1 is a ubiquitous transcription factor that participates in a wide range of 
physiological and pathophysiological processes [Gashler and Sukhatme, 1995]. The Egr-
1 promoter contains many regulatory elements, including two Sp 1 sites, five serum 
response elements (SREs) with adjacent Ets-like motifs, two cAMP response elements 
(CREs). The SREs in the Egr-1 promoter have been extensively studied. The distal SREs 
are critical for induction of Egr-1 by GH (growth hormone), PDGF (platelet- derived 
growth factor), GM-CSF (granulocyte macrophage colony-stimulating factor), urea, and 
stress. The proximal CRE is required for stimulation by GM-CSF and the distal CRE is 
required for stimulation by SAPKs (p38/stess-activated protein kinases) [reviewed in 
Duan et al., 2002]. To localize the LPA-responsive region in the Egr-1 promoter, a 
deletion analysis was performed. Our results indicated that the fold induction by LP A 
was relatively constant until deletions reached -140 bp. Further deletion resulted in a 
significant loss of activity, suggesting that the LP A response region is located within -
140bp. This area contains two SREs and two CREs. EMSA and super shift experiments 
indicated that specific SRF and CREB binding activities to the SRE and CRE of Egr-1 




EMSA results and indicated that both SREs and CREs are responsible for LP A induction 
of the Egr-1 promoter activation in RASMCs. 
In vascular tissues, LP A binds to members of a family of G protein-coupled 
receptors, EDG ( endothelial differentiation genes). Eight distinct subtypes of EDG 
receptors have been identified in mammalian cells. EDG-2 receptors are activated by 
LP A and the responses mediated by this subtype are blocked by pertussis toxin [Kou et 
al., 2002]. LP A was shown to sequentially activate PKC and MAPK in mesangial cells 
[Coy et al., 2002]. LPA was also reported to stimulate protein kinase C (PKC) in a 
pertussis toxin sensitive pathway in vascular smooth muscle cells [Seewald et al., 1999]. 
PKC- zeta was shown to mediate angiotensin II-induced and platelet derived growth 
factor (PDGF)-induced MAP kinase activation in vascular smooth muscle cells and Rat 
fibroblasts respectively [Liao et al., 1997 and van Dijk et al., 1997]. PKC -epsilon was 
also reported to activate MAPK in cat oesophagus smooth muscle cells upon induction by 
C2-ceramide [Shin et al., 2002]. Xuereb et al., 2000 reported that they were able to 
inhibit LPS-induced tissue factor synthesis in human vascular smooth muscle cells by 
disruption of ERK kinases and PKC signaling pathways. A group of kinases with PKC­
like functional structures has been described. This kinase family consists of PKCµ, its 
mouse homologue termed PKD [Johannes et al., 1994 and Valverde et al., 1994]. These 
kinases share structural homology to PKCs with respect to the catalytic domain and to the 
presence of amino-terminal cysteine fingers, defining the structural basis for lipid 
binding. PKCµ/PKD differs from PKC isozymes by an acidic domain, a PH domain 
within the regulatory region and the lack of a typical pseudo-substrate site [ Gschwendt et 
al., 1997 and Gibson et al., 1994]. PKCµ/PKD activation occurs through several 
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mediators via a PKC-dependent pathway [Zugaza et al., 1996]. PKC-epsilon was reported 
to colocalize with, phosphorylates, and activates PKC-µ in HEK293 cells [Brandlin et al., 
2002]. In another study [Hausser et al., 2001], PKC-µ was shown to selectively activate 
the MAPK pathway. A previous study indicates that LPA induces expression of the Egr-1 
transcription factor in mesangial cells. This induction was pertussis toxin sensitive and 
was blocked by a MAPK inhibitor. Oxidized phospholipids were shown to stimulate TF 
expression in human endothelial cells via activation of PKC/ERK/Egr-1 and calcium 
[Bochkov et al., 2002]. Our results also show that Pertussis toxin sensitive G-protein 
(Gai), PKC-c, PKD, and MAPK are involved in LP A-induction of TF and Egrl mRNA. 
Taken together, our results (together with the published data) suggest a signaling pathway 
in RASMCs starting by LP A activating Gai protein which in tum activate PKC- epsilon. 
PKC-epsilon then activates PKC-µ / PKD which phosphorylates MAPK. Activated 
MAPK induces Egr-1 which is involved in turning on TF gene in the nucleus (figure 46). 
Many cells which comprise the vasculature, generate reactive oxygen species (ROS) 
[Irani, 2000]. Oxidative stress is a term used to describe an imbalance between the 
production and destruction of reactive oxygen species (ROS), thereby leading to cellular 
and tissue injury [Rice-Evans and Burdon, 1994]. The common risk factors for 
atherosclerosis increase production of reactive oxygen species (ROS) by endothelial, 
vascular smooth muscle, and adventitial cells [Harrison et al., 2003]. The damage 
inflicted by ROS on cellular and extra-cellular targets such as membrane lipids, proteins, 
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Fig.46. A diagram showing one of the signaling 
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36 
Egrl (CREB, SRE) 
i N 
ROS has been identified as signaling molecules in a variety of cell types, 
including smooth muscle cells and other vascular cells. In particular, the oxidation of 
low-density lipoproteins (LDL) in the vascular wall is widely accepted to play a 
fundamental role in the pathogenesis of atherosclerosis [Shihabi et al., 2002]. 
Lysophosphatidic acid (LPA) is formed during mild oxidation of LDL and is the active 
compound in mildly oxidized LDL and minimally modified LDL [Siess et al., 1999]. 
Because of the importance of both LP A and ROS in vascular disease, we were interested 
in studying their interactions and relations at the molecular level. LP A was reported to 
stimulate ROS production in Hela cells [Chen et al., 1995]. Our results indicate that LPA 
induces ROS release in RASMCs, suggesting an important role for ROS in the athero­
and thrombogenic actions of lysophosphatidic acid. 
Increased ROS production is observed at sites of vascular injury and has been 
related to the development of restenosis/atherosclerosis [Berk, 1999]. Moreover, the 
enhanced generation of ROS promotes a procoagulant state [Ruef, 1 999]. A role of ROS 
in the control of coagulation has been suggested, and the key activator of the extrinsic 
coagulation cascade, tissue factor (TF), has been shown to be modulated by ROS in 
several cell types, including vascular cells [Herkert and Gorlach, 2002]. Our results 
indicate that LP A-induction of TF mRNA was blocked by antioxidants suggesting a role 
for ROS in the control of LPA-induction of TF expression in RASMCs. To further 
elucidate the signaling pathways involved in ROS-mediated LP A-induction of TF gene 
expression in RASMCs, ROS release was measured in quiescent RASMCs after 
stimulation with LPA (25µM) alone or after pretreatment with PTX (Goo inhibitor), GF 
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(PKC inhibitor), and UO126 (MAPK inhibitor) to determine if the same G proteins­
coupled receptors signaling pathway (involved in LPA-induced TF mRNA) is also 
involved in LP A-stimu_lated ROS release. Our results indicate that PTX (Gai inhibitor) 
and GF (pan-PKC inhibitor) failed to block this induction. In contrast, the MAPK 
inhibitor, UO-126, blocked LPA-induction of ROS production. These data suggest that 
LPA-induction of ROS release may involve an alternative signaling pathway which is 
different from the Gai protein-coupled receptor pathway. 
It is well known that several signaling pathways are activated by LP A including 
calcium mobilization and AA release. It has been reported that LP A stimulates ROS 
release in human keratinocytes by a pathway involving intracellular calcium release, 
phospholipase A2 (PLA2) stimulation, and arachidonic acid (AA) release [reviewed in 
Sekharam et al., 2000]. Arachidonic acid serves as precursor for the generation of 
bioactive lipid mediators known as eicosanoids that include prostaglandins, 
thromboxanes, and leukotrienes [Tithof et al., 1998]. Arachidonic acid metabolites are 
important regulators of inflammation, blood coagulation, and thrombosis [Marcus, 1994; 
Petrukhina and makarov, 1997]. Eicosanoids modulate physiologic processes in the 
vessel wall contributing to atherosclerosis and thrombosis, including platelet aggregation, 
control of vascular tone, and the local inflammatory response [Linton and Fazio, 2002]. 
Proliferation of vascular smooth muscle cells (VSMCs) is implicated in the pathogenesis 
of primary atherosclerosis, and restenosis following interventional revascularization 
procedures such as balloon angioplasty, arterial stenting, and by-pass surgery [Anderson 
et al., 1997]. AA has been reported to induce smooth muscle cell proliferation and 
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migration by releasing reactive oxygen species in rabbit cultured aortic smooth muscle 
cells [Nishio and Watanabe, 1997]. AA has also been reported to induce apoptosis in rat 
glioma cells and human promyelocytic leukemia cells (HL-60) by accumulating reactive 
oxygen species [Higuchi and Yoshimoto, 2002; Arita et al., 2001 ]. LTB4 [leukotriene B4 
(an arachidonic acid metabolite)] induces ROS generation in Rat-2 fibroblasts, 
neutophils, eosinophils, and other fibroblasts [reviewed in Woo et al., 2002]. AA was 
shown to enhance tissue factor expression in mononuclear cells by the cyclo-oxygenase 
pathway [Cardoy et al., 1 998]. Eicosanoids (AA metabolites) were also shown to enhance 
LPS and TNF-a -evoked expression of monocyte TF [Eilertsen et al., 2003]. Our results 
indicate that LP A stimulates rapid release of AA in RASMCs. These results also indicate 
that AA stimulates ROS release and induces TF m.RNA, suggesting its involvement in 
ROS-induction of TF expression in RASMCs upon stimulation by LPA. 
Phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of 
membrane glycerophospholipids to liberate arachidonic acid (AA). The same reaction 
also produces lysophosholipids, which represent another class of lipid mediators. So far, 
at . least 19  enzymes that possess PLA2 activity have been identified and cloned in 
mammals [Kudo and Murakami, 2001]. The secretory PLA2 (sPLA2) family, in which 
10 isozymes have been identified, consists of low-molecular weight, Ca2+-requiring 
secretory enzymes that have been implicated in a number of biological processes, such as 
modification of eicosanoid generation, inflammation, and host defense. The cytosolic 
PLA2 ( cPLA2) family consists of three enzymes, among which cPLA2alpha has been 
paid much attention by researchers as an essential component of the initiation of AA 
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metabolism. The activation of cPLA2alpha is tightly regulated by Ca2+ and 
phosphorylation. The Ca2+-independent PLA2 (iPLA2) family contains two enzymes 
and may play a major role in phospholipid remodeling. The platelet-activating factor 
(P AF) acetylhydrolase (P AF-AH) family contains four enzymes that exhibit unique 
substrate specificity toward P AF and/or oxidized phospholipids. Degradation of these 
bioactive phospholipids by PAF-AHs may lead to the termination of inflammatory 
reaction and atherosclerosis [Kudo and Murakami, 2001]. 
Atherosclerosis can be regarded as a localized inflammation of the artery wall, 
and plaque progression is substantially driven by inflammatory mediators. Lipoprotein­
associated phospholipase A2 (Lp-PLA2) is a calcium-independent serine lipase that, in 
plasma, is mostly associated with low density lipoprotein (LDL) particles. Its substrates 
include platelet-aggregating factor (P AF), and the enzyme is widely referred to in the 
literature as P AF acetylhydrolase. Oxidised LDL (formed under conditions of oxidative 
stress, such as exist in the artery wall) contains a variety of lipid peroxidation products, 
which are efficiently hydrolysed at the SN2 position by Lp-PLA2. The products are 
oxidised fatty acids plus lyso-phosphatidylcholine (PC); both have a variety of 
proinflammatory effects in many cell types, including monocyte. A proposed 
proatherogenic mechanism for this enzyme is that associated Lp-PLA2, becomes oxidised 
within the intima, providing a substrate for the enzyme. The resulting hydrolysis products 
promote the chronic inflammation that is associated with macrophage accumulation. 
Macrophages also produce and secrete further Lp-PLA2, representing one of the positive 
feedback mechanisms driving disease progression [Leach et al., 2001]. 
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LP A may be synthesized by cells either de novo from glucose through pathways 
of lipid metabolism in the endoplasmic reticulum or through liberation of precursor 
phospholipids and subsequent enzymatic conversions in membrane microvesicles 
[Goetzl, 1998; Jalink, 1994; and Gaits, 1997]. PLD first converts phosphatidylcholine to 
PA and PLA2 then hydrolyzes the sn-2 (sn-1) ester bond of PA to generate LP A. 
Exogenous LP A can also induce PLA2 to generate LP A (positive feed back mechanism) 
[Eder et al., 2000]. Our results demonstrate that LP A-induced TF mRNA was blocked in 
the cells pre-treated with ARA, Bel, and MJ 33 (PLA2 inhibitors), suggesting that at least 
some of PLA2 isoforms are involved in LPA-induced AA release. The same PLA2 
inhibitors also blocked ROS release in RASMCs suggesting that LPA-induced ROS 
release in RASMCs involves AA release by PLA2. 
LP A is known to activate arachidonic acid release, MAPK activation and calcium 
mobilization [Sekharam et al., 2000]. AA and its metabolites are implicated in the control 
of calcium homeostasis, including modulation of calcium release and calcium entry via 
voltage-gated and nonvoltage-gated pathways by AA itself or by metabolites synthesized 
via cyclooxygenase (COX), lipoxygenase (LOX), or mono-oxygenase ( cytochrome P450, 
MOX) pathways. In general, AA and its metabolites stimulate calcium mobilization [Liu 
and Rittenhouse, 2000]. AA was shown to activate MAPK in vascular smooth muscle 
cells [Kalyankrishna and Malik, 2003]. MAPK was also reported to induce ROS 
generation in human lung endothelial cells and other cells [Parinandi et al., 2002 and Kroj 
et al., 2003]. Increased intracellular calcium concentration was shown to induce TF 
expression in vascular endothelial cells [Taubman et al., 1993 and Wakita et al., 1994]. 
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Our results show that thapsigargin (intracellular calcium mobilization inducer) alone was 
able to induce TF mRNA. At the same time, BAPTA-AM (intracellular calcium chelator) 
· was able to block both LPA-induced TF mRNA and LPA-induced ROS release in 
RASMCs. Our western blot results also show that antioxidants do not block LP A­
induction of MAPK suggesting that LP A-induction of ROS release acts downstream of 
MAPK activation in RASMCs. Taken together, these data show the diverse ways and 
signaling mechanisms by which LPA can induce TF in RASMCs (figure 47). In one 
pathway, LPA activates PLA2 which releases AA from the membrane phospholipids. AA 
can then activate MAPK, ROS release, and calcium (all of them can induce TF). In 
another pathway, LP A activates MAPK which induces ROS release inducing TF. LP A 
can also induce ROS release to induce TF. 
We used HASMCs to reproduce some of the mam experiments performed 
initially in RASMCs. HASMCs are more expensive and more difficult to grow compared 
to RASMCs. We were able to reproduce most of the important data we had in RASMCs, 
including the induction of both· TF mRNA and ROS release by LP A and AA. These 
results indicate that RASMCs still represent an authentic model for studying vascular 
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Fig. 47. A diagram showing another set of signaling pathways by 
which LP A induces TF. 
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VI. SUMMARY AND CONCLUSION 
Lysophosphatidic acid (LPA) is a potent bioactive phospholipids with specific 
and multiple effects on blood cells and cells of the vessel wall. LP A is a component of 
oxidized low density lipoproteins (oxLDL) which has been shown to accumulate in 
human atherosclerotic plaques. Tissue factor is the principal initiator of blood 
coagulation. The active form of TF has been shown to be present in specimens of human 
coronary artery in association both with acellular lipid areas and with macrophages and 
smooth muscle cells, which suggests that TF plays a major role in determining plaque 
thrombogenicity. The generation of ROS, which act as a signaling molecule in the 
vascular system, is enhanced in response to injury and has been associated with a 
procoagulant state and the progression of atherosclerotic disease. 
Our group has recently reported that LP A markedly induces TF mRNA, TF 
protein, and TF surface activity in RASMCs. It has also been reported that LPA inducees 
ROS release in human keratinocytes. Little is known about the regulation of TF by LP A 
in SMC which is a major player in the process of atherosclerosis. The present study 
investigated the regulation of TF expression by LP A in RASMCs. Data generated by this 
study demonstrate that LP A markedly induces TF expression in RASMCs and HASMCs. 
The signaling pathways involved are multiple. One signaling pathway demonstrates that 
LPA activates Gai protein which in turn activate PKC- epsilon that activates PKC-µ I 
PKD which phosphorylates MAPK to induce Egr-1 that is involved in turning on TF gene 
in the nucleus. Another pathway indicates that LP A activates PLA2 which releases AA 
from the membrane phospholipids. AA can then activate MAPK, ROS release, and 
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calcium (all of them can · induce TF). In another pathway, LPA activates MAPK which 
induces ROS release inducing TF. LP A can also induce ROS release to induce TF. Our 
data suggest that elevated LPA have potential atherogenic and thrombogenic actions by 
inducing TF expression an ROS release. Understanding the mechanisms involved could 
provide new insights into atherosclerosis, thrombosis and restenosis after angioplasty. It 
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Fig.1. Induction of TF mRNA in response to LPA in 
RASMC. LP A was added to quiescent RASMC at the 
concentrations indicated above each lane. Total RNA (6 µg per 
lane) was isolated from cells incubated with LP A for 1 .5 h, 
and TF mRNA levels were determined by northern blotting. 
Rat TF cDNA fragment ( 685 bp) was used as a probe. 28S and 
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Fig. 2. Time course of LPA induction of TF mRNA. LPA 
(25µM) was added to quiescent RASMC at the times 
indicated. Total mRNA was isolated, and TF mRNA levels 
were determined by Northern blot analysis. A rat TF cDNA 
fra�ent ( 685bp) was used as a probe. 1 8S rRNA was 
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Fig.3. Nuclear protein binding activity is induced by 
LPA at the Egrl site (not at SPl, NFKB, APl). Four 
oligonucleotides (SPl ,NFKB, APl ,and Egrl) were 
individually incubated with cell lysates from 
unstimulated RASMCs, or cells stimulated with LP A for 
the times indicated. Protein-DNA complexes were 








Fig.4. Identification of the protein present in Egrl 
protein_DNA complex II using Egrl _specific antibody. Egrl 
oligonucleotides were incubated with nuclear extracts from 
LPA-stimulated (lh) RASMCs in the absence or presence of2 
µ1 of Egrl antibody. The Egrl complexes are separated using 6 
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Fig. 5. Time course of LP A induction of Egrl 
mRNA. LPA (25µM) was added to quiescent 
RASMC at the times indicated. Total mRNA was 
isolated, and Egrl mRNA levels were determined by 
Northern blot analysis. A rat Egrl cDNA fragment 
(l .5kb.) was used as a probe. 
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Fig.6. Egrl can transactivate the TF promoter. RASMCs · were 
trasfected with a plasmid containing the wild type TF promoter cloned 
upstream of the luciferase reporter gene [pTF (-258)]. Another set of 
cells was cotransfected with the same plasmid and another plasmid 
expressing Lac Z (pcDNA3. l/LacZ). A third set of cells was 
cotransfected with both pTF (-258) and another plasmid expressing Egrl 
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Fig.7. Time course of LPA induction of Egrl 
protein in RASMCs. Quiescent RASMCs were 
stimulated with 25µM of LPA, and at the times 
indicated, cell lysates were analysed by 10% SDS­
PAGE and transferred to a polyvinylidine difluoride 
membrane. Egrl protein was detected with antibody 
against aegrl(C-19). Actin protein was used to 
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Fig.8. A diagram representing mouse Egrl 
promoter fragment (-620/+21). 
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Fig.9. Localization of the LPA-responsive region in the Egrl 
promoter. A series of deleted Egrl promoter constructs was made (see 
"experimental procedures,,). Transfected RASMCs were made 
quiescent for 48 h before the addition of 25 µM LPA for 3.5 h. Fold 
induction is the luciferase (luc.) of transfected cells stimulated with 
LP A compared with unstimulated contrls. 
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Fig.10. Nuclear protein binding activity is 
induced by LPA at the SRE site. 
Radiolabelled SRE oligonucleotides were 
incubated with cell lysates from unstimulated 
RASMCs, or cells stimulated with LP A for the 
times indicated. Protein-DNA complexes were 
analyzed by EMSA using a 6% polyacrylamide 
gel. 
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Fig. 11 .  Nuclear protein 
binding activity is induced by 
LPA at the CRE site. 
Radiolabelled CRE oligo­
nucleotides were incubated with 
cell lysates from unstimulated 
RASMCs, or cells stimulated 
with LPA for the times 
indicated. Protein-DNA 
complexes were analyzed by 
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Fig.12. Specific nuclear protein binding activity is induced 
by LP A at the SRE site. Cell lysates from quiescent 
RASMCs or RASMCs stimulated with LP A for IO  minutes 
were pre- incubated for 20 minutes with: 50 molar excess of 
unlabelled SRE oligonucleotides (3, 4), radiolabelled mutated 
SRE oligonucleotides (5, 6), 2µ1 of SRF antibody (6, 7), 2µ1 of 
phosphorylated SRF antibody (9, 10). They were then 
incubated with radiolabelled SRE oligonucleotides for another 
20 minutes (1, 2, 3, 4, 7, 8, 9, 10). Protein DNA complexes 
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Fig.13. Specific nuclear protein 
binding activity is induced by LP A 
at the CRE site. Cell lysates from 
quiescent RASMCs or RASMCs 
stimulated with LP A for 10 minutes 
were pre- incubated for 20 minutes . 
with: 50 molar excess of unlabelled 
CRE oligonucleotides (1, 2), 
radio labelled mutated SRE 
oligonucleotides (5, 6), 1 µl of CRE 
antibody (6, 7), 1 µl of 
phosphorylated CRE antibody (9, 
10). They were then incubated with 
radiolabelled CRE oligonucleotides 
for another 20 minutes (1, 2, 3, 4, 7, 
8, 9, 10). Protein DNA complexes 
were then analyzed by EMSA using a 
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Fig.14.Functional analysis of the Egrl promoter. RASMCs were 
transfected with th native Egrl promoter (-140/+21) or mutated Egrl 
promoter constructs [(-140/+21)dmSRE and (-140/+21)dmCRE)] . 
Transfected cells were starved for 48h before the addition of LP A 
(25µM) for 3h. Fold induction is the luciferase activity of transfected 
cells stimulated with LP A compared with unstimulated controls (n = 
number of experiments; in each, transfections were performed in 
duplicates). 
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Fig.15. Northern blot analysis shows that 
pretreatment of quiescent RASMCs with 
PTX, R031, PD98059, 00126 block LPA­
induced TF mRNA, whereas, G073122, 
073122, and 073343 were not effective. 
Quiescent RASMCs were stimulated with 
LP A (25 µM) alone for 1 .5 hor after 
pretreatment with PTX (16h), RO31 ,  
PD98059, UO126, 006976, U73122, and 
U73343 ( each for 30 min.) in the 
concentrations indicated above. A rat TF 
cDNA fragment (685bp) was used as a probe. 
28S and 18S rRNA were visualized by 
ethidium bromide staining. 
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Fig.16. Northern blot analysis shows that pretreatment of 
quiescent RASMCs with chelerythrin chloride and GF 
block LPA-induced TF mRNA. Quiescent RASMCs were 
stimulated with LP A (25 µM) alone for 1.5 h or after 
pretreatment with chelerythrin chloride and GF ( each for 30 
min.) in the concentrations indicated above. A rat TF cDNA 
fragment (685bp) was used as a probe. 28S and 1 8S 
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Fig.17. Northern blot analysis shows that pretreatment of quiescent 
RASMCs with U0-126, SB, and Sp block LPA-induced TF mRNA. 
Quiescent RASMCs were stimulated with LPA (25µM) alone for 1.5 h or 
after pretreatment with Resveratrol, SB, Sp (each for 30 min.) in the 
concentrations indicated above. A rat TF cDNA fragment (685bp) was 
used as a probe. 28S and 1 8S rRNA were visual ized by ethidium 
bromide staining. 
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Fig.18. Northern blot analysis shows that pretreatment of quiescent 
RASMCs with PTX (120ng/ml), UO-126 (l0µM), GF (µM), and 
Resveratrol (100 µM) block LPA-induced Egr-1 mRNA, whereas, SB 
(2,5µM), Sp (2µM), U73122 (5µM) was not effective. Quiescent RASMCs 
were stimulated with LPA (25µM) alone for 1.5 h or after pretreatment with 
PTX (120ng/ml) for 16h, UO-126 (lOµM), GF (µM), and Resveratrol (100 
µM), SB (2,SµM), Sp (2µM), U73122 (SµM) (each for 30 min.). Total mRNA 
was isolated, and Egrl mRNA levels were determined by northern blot 
analysis. A rat Egrl cDNA fragment (1.Skb.) was used as a probe. 
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Fig.19. Northern blot analysis shows that LPA-induced 
TF mRNA was only blocked in quiescent RASMCs 
infected by PKCE-dn. Total mRNA was isolated , and 
TF mRNA levels were determined by Northern blot 
analysis. A rat TF cDNA fragment (685bp) was used 
as a probe. 
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Fig.20. Northern blot analysis shows that LP A-induced TF 
mRNA was not blocked in quiescent RASMCs infected by 
PKC f .. Total mRNA was isolated , and TF mRNA levels 
were determined ey Northern blot analysis. A rat TF 
cDNA fragment (685bp) was used as a probe. 
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Fig.21. LPA stimulates ROS release in RASMCS. Serum starved cells 
were incubated with luminol and HRP and treated with either LP A 
(25 µM) alone or pre-treated with NAC for 30 min and then treated with 
LP A (25 µM). chemiluminescence was recorded immediately at 10 
seconds intervals and then every 5 minutes after 30 minutes. For clarity, 
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Fig.22. Northern blot analysis shows that LP A 
induction of TF mRNA is blocked by 
antioxidants. Quiescent RASMCs were 
stimulated with LP A (25 µM) for 1. 5 h alone or 
after pretreatment with Na F. [sodium formate 
{l0OmM)] for 24h, Desf. [Desferoxamine 
(50mM)], NAC [N-Acetyl Cysteine {lOmM)], DPI 
[diphenyleneiodonium chloride (25µM)] for 30 
minutes each. A rat TF cDNA fragment (685bp) 
was used as a probe. 28S and 1 8S rRNA 
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Fig.23. PTX (Gai inhibitor) does not block LPA-induced ROS release in 
RASMCS. Quiescent RASMCs were incubated with luminol and HRP, pre­
treated with PTX for 16 h and then treated with LPA (25µM). 
Chemiluminescence was recorded immediately at 10 seconds intervals and 
then every 5 minutes after 30 minutes. For clarity, data from some time 
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Fig.24. GF (PKC inhibitor) does not block LPA-induced ROS release 
in RASMCS. Quiescent RASMCs were incubated with luminol and 
HRP, ,stimulated with LP A (25 µM) alone or after pre-treatment with GF 
for 30 minutes. Ch�miluminescence was recorded immediately at 60 
seconds intervals and then every 5 minutes after 30 minutes. For clarity, 
data from some time points are not shown in the graph. 
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Fig.25. 00126 (MAPK inhibitor) blocks LPA-induced ROS release in 
RASMCS. Quiescent RASMCs were incubated with luminol and HRP, 
stimulated with LP A (25 µM) alone or after pre-treatment with UO 126 
(1 0µM) for 30 minutes. Chemiluminescence was recorded immediately at 
60 seconds intervals and then every 5 minutes after 30 minutes. For 
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Fig.26. LPA stimulates AA release in RASMCS. Release of [3H]AA in 
the extracellular medium was measured in the presence of 0.1 % albumin. 








0 30 60 90 120 240 360 480 
Fig.27. Time course of AA induction of TF mRNA. AA 
(l0µM) was added to quiescent RASMC at the times indicated. 
Total mRNA was isolated, and TF mRNA levels were 
determined by Northern blot analysis. A rat TF cDNA fragment 
(685bp) was used as a probe. 1 8S rRNA was visualized by 
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Fig.28. AA stimulates ROS release in RASMCS. Serum 
starved cells were incubated with luminol and HRP and 
treated with either AA (1 0µM) alone or pre-treated with 
NAC (1 0µM) for 30 min and then treated with AA (1 0µM). 
chemiluminescence was recorded immediately at 1 0  seconds 
intervals and then every 5 minutes after 30 minutes. For 
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Fig.29. Northern blot analysis shows that AA induction of TF 
mRNA is blocked by antioxidants. Quiescent RASMCs were 
stimulated with AA (SOµM) for 1.5 h alone or after pretreatment 
with Na F. [sodium formate (lOOmM)] for 24h, Desf. 
[Desferoxamine (50mM)], NAC [N-Acetyl Cysteine (lOmM)], DPI 
[diphenyleneiodonium chloride (25µM)] for 30 minutes each. A rat 
TF cDNA fragment (685bp) was used as a probe. 28S rRNA was 
visualized by ethidium bromide staining. 
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Fig.30. Northern blot analysis shows that LPA induction of TF mRNA is 
blocked by PLA2 inhibitors. Quiescent RASMCs were stimulated with LP A 
(25µM) for 1 .5 h alone or after pretreatment with the following PLA2 inhibitors: 
MAFP (lOµM), ARA (aristolochic acid, lOµM), BPB (lOµM), Bel {lOµM), and 
MJ33 (lOµM), each for 30 minutes. A rat TF cDNA fragment (685bp) was used 
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Fig.31. ARA (PLA2 inhibitor) blocks LPA-induced ROS release in 
RASMCS. Quiescent RASMCs were incubated with luminol and HRP and 
treated with either LPA (25µM) alone or pre-treated with ARA (loµM) for 
30 min and then treated with LP A (25 µM). Chemiluminescence was 
recorded immediately at 60 seconds intervals and then every 5 minutes after 
30 minutes. For clarity, data from some time points are not shown in the 
graph. 
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Fig.32. Bel (PLA2 inhibitor) blocks LPA-induced ROS release in RASMCs. 
Quiescent RASMCs were incubated with luminol and HRP and treated with 
either LP A (25 µM) alone or pre-treated with Bel ( 5 µM) for 30 min and then 
treated with LP A (25 µM). Chemiluminescence was recorded immediately at 60 
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Fig.33. MJ33 (PLA2 inhibitor) blocks LPA-induced ROS release in 
RASMCs. Quiescent RASMCs were incubated with luminol and HRP and 
treated with either LPA (25µM) alone or pre-treated with MJ33 (lOµM) for 
30 min and then treated with LP A (25 µM). Chemiluminescence was 
recorded immediately at 60 seconds intervals and then every 5 minutes 
after 30 minutes. For clarity, data from some time points are not shown in 
the graph. 
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Fig.34. Western bolt analysis shows that Anti-oxidants do not block 
LP A-induced MAPK. Quiescent RASMCs were stimulated with LP A 
(25µM) alone for 3 minutes or after pretreatment with Na F. [sodium 
formate (lOOmM)] for 24h, Desf. [Desferoxamine (50mM)], NAC [N­
Acetyl Cysteine (l OmM)], DPI [diphenyleneiodonium chloride (25µM)] 
for 30 minutes each. Cell lysates were analysed by 8% SOS-PAGE and 
transferred to a polyvinylidine difluoride membrane. Phosphorylated 
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Fig.35. U0-126 (MAPK inhibitor) blocks AA-induced ROS release in 
RASMCs. Quiescent RASMCs were · incubated with luminol and HRP 
and treated with either AA (1 0µM) alone or after pre-treatment with UO-
126 (lOµM) for 30 minutes. Chemiluminescence was recorded 
immediately at 60 seconds intervals and then every 5 minutes after 30 
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Fig.36. Northern blot shows that calcium 
is involved in LPA-induced TF mRNA. 
Quiescent RASMCs were stimulated with 
thapsigargin alone (lOµM) for 1 .5 h, LPA 
alone (25µM) for 1 .5 h or after pretreatment 
with BAPTA-AM (40µM) for 30 minutes. A 
rat TF cDNA fragment (685bp) was used 
as a probe. 28S and 1 8S rRNA were 
visual ized by ethid ium bromide staining. 
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Fig.37. BAPT-AM (intracellular calcium chelator) blocks LPA-induced 
ROS release in RASMCs. Quiescent RASMCs were incubated with 
luminol and HRP and treated with either LP A (25 µM) alone or pre-treated 
with BAPT-AM (40µM) for 30 min and then treated with LPA (25µM). 
Chemiluminescence was recorded immediately at 60 seconds intervals and 
then every 5 minutes after 30 minutes. For clarity, data from some time 









Fig.38. Northern blot shows that calcium is 
involved in AA-induced TF mRNA. Quiescent 
RASMCs were stimulated with AA alone 
(50µM) for 1.5 h or after pretreatment with 
BAPTA-AM (40µM) for 30 minutes. A rat TF 
cDNA fragment (685bp) was used as a probe. 28S 
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Fig.39. BAPT-AM (intracellular calcium chelator) blocks AA-induced 
ROS release in RASMCs. Quiescent RASMCs were incubated with 
lurninol and HRP and treated with either AA (S0µM) alone or pre-treated 
with BAPT-AM (40µM) for 30 min and then treated with AA (S0µM). 
Chemiluminescence was recorded immediately at 60 seconds intervals and 
then every 5 minutes after 30 minutes. For clarity, data from some time 
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Fig.40. Induction of TF mRNA in response 
to LPA in HASMC. LPA was added to 
quiescent HASMC at the concentrations 
indicated above each lane. Total RNA (6 µg 
per lane) was isolated from cells incubated 
with LPA for 1 .5 h, and TF mRNA levels were 
determined by northern blotting. Human TF 
cDNA fragment (641 bp) was used as a probe. 
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Fig.41. Northern blot analysis shows that pretreatment of quiescent 
HASMCs with PTX, GF, Resveratrol block LPA-induced TF 
mRNA,whereas, GO73122, and 073122 were not effective. Quiescent 
HASMCs were stimulated with LP A (25 µM) alone for 1.5 h or after 
pretreatment with PTX (120ng/ml for 16h), 006976 
(lOOµM),Resveratrol (lOOµM), and U73122 (5µM) (each for 30 min.) A 









Fig.42. Northern · blot analysis shows that 
pretreatment of quiescent HASMCs with 00126 
and PD block LPA-induced TF mRNA. Quiescent 
HASMCs were stimulated with LPA (25µM) alone for 
1 .5 h or after pretreatment with UO126 ( l 0µM) and 
PD (3µM). A human TF cDNA fragment (641bp) was 
used as a probe. 
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Fig.43. Northern blot analysis shows that pretreatment of 
quiescent HASMCs with R031 and chelerythrin chloride 
block LPA-induced TF mRNA, whereas SP and SB were 
not effective. Quiescent HASMCs were stimulated with LP A 
(25 µM) alone for 1.5 h or after pretreatment with RO3 1 
(.SµM), chelerythrin chloride (3µM), SP (5µM), and SB (2µM). 
A human TF cDNA fragment ( 641 bp) was used as a probe. 
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Fig.44. Northern blot analysis shows that LPA induction of 
TF mRNA is blocked by DPI. Quiescent RASMCs were 
stimulated with LPA (25)µM) for 1.5 h alone or after 
pretreatment with Na F. [sodium formate (lOOmM)] for 24h, 
Desf. [Desferoxamine (50mM)], NAC [N-Acetyl Cysteine 
(lOmM)], DPI [diphenyleneiodonium chloride (25µM)] for 30 
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Fig.45. Northern blot analysis shows that AA induction 
of TF mRNA is blocked by DPI in HASMCs. Quiescent 
HASMCs were stimulated with AA (50µM) for 1.5 h 
alone or after pretreatment with Na F. [sodium formate 
(lOOmM)] for 24h, Desf. [Desferoxamine (50mM)], NAC 
[N-Acetyl Cysteine (lOmM)], DPI [ diphenyleneiodonium 
chloride (25µM)] for 30 minutes each. A rat TF cDNA 
fragment ( 685bp) was used as a probe. 
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